Subcutaneous Bioavailability of Recombinant Human Erythropoietin in Chronic Renal Failure Patients

Stimulation of erythropoietin secretion by continuous subcutaneous infusion of recombinant human GH in anemic patients with chronic renal failure.

We have investigated the effect of human GH on erythropoietin (EPO) secretion in eight anemic patients with chronic renal failure (CRF) (three males and five females, aged from 46 to 83 years). Recombinant human GH was infused subcutaneously at a flow rate of 2 microg/kg body weight per 0.1 ml/h for 72 h using a portable infusion pump. Blood samples were obtained immediately before and 2, 4, 6,...

Human erythropoietin gene therapy for patients with chronic renal failure.

Gene therapy holds a major promise. However, until now, this promise was fulfilled only in few cases, in rare genetic diseases. One very common clinical condition is anemia. Patients with anemia of chronic renal failure are treated with erythropoietin. The objective of this study was to develop a therapeutic platform for serum-secreted proteins like erythropoietin. We developed a tissue protein...

the impact of human recombinant erythropoietin on renal function in patients with chronic kidney disease

Subcutaneous versus intravenous recombinant human erythropoietin administration in hemodialysis patients.

The Effect of Dignity Therapy on Human Dignity in Patients with Chronic Renal Failure Undergoing Hemodialysis

Background: Chronic renal failure is a life-threatening condition; patients due to the prolonged stress are very susceptible to mental health problems. Dignity therapy is a novel therapeutic approach to the treatment of psychological problems for patients who suffer from life-threatening illnesses. Aim: This study examined the impact of dignity therapy on human dignity in patients undergoing he...